Ironwood Pharmaceuticals Inc (NASDAQ: IRWD)’s stock price has plunge by -1.15relation to previous closing price of 8.71. Nevertheless, the company has seen a -0.81% plunge in its stock price over the last five trading sessions. InvestorPlace reported 2024-03-05 that Healthcare stocks, especially biotech companies, are very risky for investors. Their share price can be highly volatile and surge higher or plummet lower based on news regarding a clinical trial, treatment authorization, or any number of events that could be or break a company.
Is It Worth Investing in Ironwood Pharmaceuticals Inc (NASDAQ: IRWD) Right Now?
Moreover, the 36-month beta value for IRWD is 0.56. Analysts have varying opinions on the stock, with 2 analysts rating it as a “buy,” 3 as “overweight,” 5 as “hold,” and 1 as “sell.”
The public float for IRWD is 151.60M and currently, short sellers hold a 12.38% of that float. On April 02, 2024, IRWD’s average trading volume was 4.90M shares.
IRWD’s Market Performance
The stock of Ironwood Pharmaceuticals Inc (IRWD) has seen a -0.81% decrease in the past week, with a -8.70% drop in the past month, and a -24.93% fall in the past quarter. The volatility ratio for the week is 4.42%, and the volatility levels for the past 30 days are at 5.03% for IRWD. The simple moving average for the last 20 days is -2.59% for IRWD stock, with a simple moving average of -18.83% for the last 200 days.
Analysts’ Opinion of IRWD
Many brokerage firms have already submitted their reports for IRWD stocks, with Craig Hallum repeating the rating for IRWD by listing it as a “Buy.” The predicted price for IRWD in the upcoming period, according to Craig Hallum is $21 based on the research report published on January 17, 2024 of the current year 2024.
Wells Fargo, on the other hand, stated in their research note that they expect to see IRWD reach a price target of $20. The rating they have provided for IRWD stocks is “Overweight” according to the report published on December 14th, 2023.
Jefferies gave a rating of “Buy” to IRWD, setting the target price at $21 in the report published on November 09th of the previous year.
IRWD Trading at -28.77% from the 50-Day Moving Average
After a stumble in the market that brought IRWD to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -45.16% of loss for the given period.
Volatility was left at 5.03%, however, over the last 30 days, the volatility rate increased by 4.42%, as shares sank -5.02% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -29.31% lower at present.
During the last 5 trading sessions, IRWD fell by -0.81%, which changed the moving average for the period of 200-days by -21.94% in comparison to the 20-day moving average, which settled at $8.82. In addition, Ironwood Pharmaceuticals Inc saw -24.74% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at IRWD starting from Duane Jon R, who purchase 6,920 shares at the price of $8.70 back on Mar 06 ’24. After this action, Duane Jon R now owns 121,028 shares of Ironwood Pharmaceuticals Inc, valued at $60,204 using the latest closing price.
Emany Sravan Kumar, the SVP, Chief Financial Officer of Ironwood Pharmaceuticals Inc, purchase 10,684 shares at $9.38 during a trade that took place back on Mar 04 ’24, which means that Emany Sravan Kumar is holding 301,733 shares at $100,216 based on the most recent closing price.
Stock Fundamentals for IRWD
Current profitability levels for the company are sitting at:
- -2.12 for the present operating margin
- 1.0 for the gross margin
The net margin for Ironwood Pharmaceuticals Inc stands at -2.26. The total capital return value is set at -4.81. Equity return is now at value -654.88, with -127.54 for asset returns.
Based on Ironwood Pharmaceuticals Inc (IRWD), the company’s capital structure generated 1.98 points at debt to capital in total, while cash flow to debt ratio is standing at 0.26. The debt to equity ratio resting at -2.02. The interest coverage ratio of the stock is -43.4.
Currently, EBITDA for the company is 210.61 million with net debt to EBITDA at -0.69. When we switch over and look at the enterprise to sales, we see a ratio of 4.45. The receivables turnover for the company is 3.43for trailing twelve months and the total asset turnover is 0.94. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.84.
Conclusion
To wrap up, the performance of Ironwood Pharmaceuticals Inc (IRWD) has been bad in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
